Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017156489) INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/156489 International Application No.: PCT/US2017/021959
Publication Date: 14.09.2017 International Filing Date: 10.03.2017
IPC:
C07C 235/66 (2006.01) ,C07C 237/48 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
235
Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
42
having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
66
with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
237
Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
48
having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
Applicants:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY [US/US]; Office of the General Counsel Building 170, 3rd Floor, Main Quad P.O. Box 20386 Stanford, California 94305-2038, US
Inventors:
SAKAMOTO, Kathleen Miho; US
SMITH, Mark; US
CHAE, Hee-Don; US
MITTON, Bryan; US
COX, Nicholas Raymond; US
Agent:
FOULDS, Glenn J.; US
Priority Data:
62/307,11911.03.2016US
Title (EN) INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA
(FR) INHIBITEURS DE L'INTERACTION CREB-CBP POUR LE TRAITEMENT DE LA LEUCÉMIE
Abstract:
(EN) Compounds and methods are provided for inhibiting a CREB-CBP protein-protein interaction in a sample. In some cases, the method includes modulating transcription of CREB in a cell that overexpresses CREB. Also provided are methods of inhibiting the proliferation of a cancer cell. The subject CREB transcription inhibitor compounds include a substituted salicylamide or a prodrug thereof. Methods of alleviating symptoms associated with cancer (e.g., Acute Myeloid Leukemia (AML) or Acute Lymphomblastic Leukemia (ALL)) in a subject in need thereof are also provided. Pharmaceutical compositions including the subject compounds find use in treating cancer. The subject compounds may be formulated or provided to a subject in combination with a second agent, e.g. an anticancer agent.
(FR) L'invention concerne des composés et des procédés pour inhiber une interaction protéine-protéine CREB-CBP dans un échantillon. Dans certains cas, le procédé comprend la modulation de la transcription de CREB dans une cellule qui surexprime CREB. L'invention concerne également des procédés d'inhibition de la prolifération d'une cellule cancéreuse. Les composés inhibiteurs de la transcription de CREB de l'invention comprennent un salicylamide substitué ou un promédicament correspondant. L'invention concerne également des procédés de soulagement de symptômes associés au cancer (par exemple, une leucémie myéloïde aiguë (LMA) ou une leucémie lymphoblastique aiguë (LLA)) chez un sujet qui en a besoin. Des compositions pharmaceutiques comprenant les composés de l'invention trouvent une utilisation dans le traitement du cancer. Les composés selon l'invention peuvent être formulés ou administrés à un sujet en combinaison avec un deuxième agent, par exemple un agent anticancéreux.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)